Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3181183rdf:typepubmed:Citationlld:pubmed
pubmed-article:3181183lifeskim:mentionsumls-concept:C0334419lld:lifeskim
pubmed-article:3181183lifeskim:mentionsumls-concept:C0028066lld:lifeskim
pubmed-article:3181183lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:3181183lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:3181183lifeskim:mentionsumls-concept:C1554963lld:lifeskim
pubmed-article:3181183pubmed:issue7-8lld:pubmed
pubmed-article:3181183pubmed:dateCreated1988-12-12lld:pubmed
pubmed-article:3181183pubmed:abstractTextFollowing a case report that oral nifedipine can suppress the secretion of noradrenaline by phaeochromocytoma, we examined the effect of nifedipine on the tumour kinetics of tracer 131I-meta-iodobenzylguanidine (131I-mIBG) in five patients referred for mIBG radionuclide therapy for disseminated malignant phaeochromocytoma. In one subject a striking modification of mIBG kinetics was found that resulted in a doubling of the absorbed dose to tumour while the patient was taking nifedipine. At the same time, urinary excretion of noradrenaline was suppressed by a factor of three. The effect of nifedipine in this patient was confirmed when tracer studies were repeated nine months later. The changes in tumour kinetics were shown to be due to prolonged retention of mIBG rather than increased tumour blood flow or alteration of the curve of mIBG plasma concentration as a function of time.lld:pubmed
pubmed-article:3181183pubmed:languageenglld:pubmed
pubmed-article:3181183pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3181183pubmed:citationSubsetIMlld:pubmed
pubmed-article:3181183pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3181183pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3181183pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3181183pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3181183pubmed:statusMEDLINElld:pubmed
pubmed-article:3181183pubmed:issn0340-6997lld:pubmed
pubmed-article:3181183pubmed:authorpubmed-author:FlemingJ SJSlld:pubmed
pubmed-article:3181183pubmed:authorpubmed-author:AckeryD MDMlld:pubmed
pubmed-article:3181183pubmed:authorpubmed-author:BlakeG MGMlld:pubmed
pubmed-article:3181183pubmed:authorpubmed-author:ZivanovicM...lld:pubmed
pubmed-article:3181183pubmed:authorpubmed-author:LewingtonV...lld:pubmed
pubmed-article:3181183pubmed:issnTypePrintlld:pubmed
pubmed-article:3181183pubmed:volume14lld:pubmed
pubmed-article:3181183pubmed:ownerNLMlld:pubmed
pubmed-article:3181183pubmed:authorsCompleteYlld:pubmed
pubmed-article:3181183pubmed:pagination345-8lld:pubmed
pubmed-article:3181183pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:meshHeadingpubmed-meshheading:3181183-...lld:pubmed
pubmed-article:3181183pubmed:year1988lld:pubmed
pubmed-article:3181183pubmed:articleTitleModification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.lld:pubmed
pubmed-article:3181183pubmed:affiliationDepartment of Nuclear Medicine, Southampton General Hospital, UK.lld:pubmed
pubmed-article:3181183pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3181183lld:pubmed